https://pittplusme.org/study/1872
M17-238: Evaluating Study Drug ABBV-157 in People with Psoriasis
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have psoriasis? Are you 18 and 75 years old? You may be able to participate in a study to find out how much of a study drug called ABBV-157 is absorbed into the blood stream, how the body handles the study drug, as well as the safety, and tolerability of taking capsules of the study drug in adults. Compensation is provided.
IRB: SSU00137852
- AbbVie, Inc. - M17-238, A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Subjects with Chronic Plaque Psoriasis (Pro00034442)
AGE:
18-75
DURATION:
About 2.5 months total
VISITS:
Multiple
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$324 per visit & some travel expenses reimbursed
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.